The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

M Zonneveld, HJ Flink, E Verheij-Hart, H Senturk, S Zeuzem, US Akarca, Y Cakaloglu, C Simon, TMK So, G Gerken, Rob de Man, Bettina Hansen, Solko Schalm, HLA Janssen

Research output: Contribution to journalArticleAcademicpeer-review

69 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1163-1171
Number of pages9
JournalAlimentary Pharmacology & Therapeutics
Issue number9
Publication statusPublished - 2005

Research programs

  • EMC MM-04-20-02-A
  • EMC NIHES-01-64-03

Cite this